Kesler Norman & Wride LLC Acquires Shares of 3,477 DaVita Inc. (NYSE:DVA)

Kesler Norman & Wride LLC acquired a new stake in shares of DaVita Inc. (NYSE:DVA) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 3,477 shares of the company’s stock, valued at approximately $571,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Chapin Davis Inc. lifted its position in DaVita by 4.3% during the third quarter. Chapin Davis Inc. now owns 16,768 shares of the company’s stock valued at $2,749,000 after buying an additional 693 shares during the period. GAMMA Investing LLC lifted its position in DaVita by 22.3% during the third quarter. GAMMA Investing LLC now owns 1,315 shares of the company’s stock valued at $216,000 after buying an additional 240 shares during the period. Handelsbanken Fonder AB lifted its position in DaVita by 13.9% during the third quarter. Handelsbanken Fonder AB now owns 13,900 shares of the company’s stock valued at $2,279,000 after buying an additional 1,700 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of DaVita in the 2nd quarter worth about $2,314,000. Finally, Point72 Asia Singapore Pte. Ltd. raised its position in shares of DaVita by 60.2% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,498 shares of the company’s stock worth $208,000 after purchasing an additional 563 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on DVA shares. TD Cowen lifted their price target on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Bank of America lifted their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Finally, Truist Financial lifted their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $159.00.

DaVita Price Performance

NYSE DVA opened at $154.35 on Wednesday. DaVita Inc. has a one year low of $71.51 and a one year high of $166.04. The stock has a 50-day moving average of $152.87 and a 200 day moving average of $143.27. The company has a market capitalization of $12.95 billion, a price-to-earnings ratio of 17.54, a PEG ratio of 0.92 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.15 billion. During the same period last year, the company earned $2.08 EPS. DaVita’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, sell-side analysts forecast that DaVita Inc. will post 9.99 EPS for the current year.

Insider Buying and Selling at DaVita

In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the transaction, the chief operating officer now owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 173,482 shares of company stock worth $27,387,069 in the last three months. 2.00% of the stock is currently owned by company insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.